UFP Technologies (UFPT) Margin Dip To 11.3% Tests Bullish MedTech Growth Narrative

Simply Wall St.

05/06

UFP Technologies (UFPT) has put fresh numbers on the board for Q1 2026, with recent quarterly revenue sitting around US$148.9 million in Q4 2025, basic EPS of US$2.28 and trailing twelve month EPS of ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2633134978"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633134978\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633134978?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2042000-choice1-main-header/1585186562856","is_english":true,"pubTime":"2026-05-06 20:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633134978","market":"nz","top_or_hot":-1,"title":"UFP Technologies (UFPT) Margin Dip To 11.3% Tests Bullish MedTech Growth Narrative","media":"Simply Wall St.","content":"<div>\n<p>UFP Technologies (UFPT) has put fresh numbers on the board for Q1 2026, with recent quarterly revenue sitting around US$148.9 million in Q4 2025, basic EPS of US$2.28 and trailing twelve month EPS of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-ufpt/ufp-technologies/news/ufp-technologies-ufpt-margin-dip-to-113-tests-bullish-medtec\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UFP Technologies (UFPT) Margin Dip To 11.3% Tests Bullish MedTech Growth Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUFP Technologies (UFPT) Margin Dip To 11.3% Tests Bullish MedTech Growth Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-06 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-ufpt/ufp-technologies/news/ufp-technologies-ufpt-margin-dip-to-113-tests-bullish-medtec><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>UFP Technologies (UFPT) has put fresh numbers on the board for Q1 2026, with recent quarterly revenue sitting around US$148.9 million in Q4 2025, basic EPS of US$2.28 and trailing twelve month EPS of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-ufpt/ufp-technologies/news/ufp-technologies-ufpt-margin-dip-to-113-tests-bullish-medtec\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLSX","symbol_name":"Tradr 2X Long BLSH Daily ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-ufpt/ufp-technologies/news/ufp-technologies-ufpt-margin-dip-to-113-tests-bullish-medtec","article_id":"2633134978","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2042000-choice1-main-header/1585186562856"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-ufpt/ufp-technologies/news/ufp-technologies-ufpt-margin-dip-to-113-tests-bullish-medtec","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633134978","pubTimestamp":1778071082,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"UFP Technologies (UFPT) has put fresh numbers on the board for Q1 2026, with recent quarterly revenue sitting around US$148.9 million in Q4 2025, basic EPS of US$2.28 and trailing twelve month EPS of US$8.87 helping frame the latest report. Over the last year, the company has seen total revenue move from US$504.4 million on a trailing basis in Q4 2024 to US$602.8 million in Q4 2025. Over the same period, trailing net income excluding extra items shifted from US$59.0 million to US$68.3 million...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLSX":"Tradr 2X Long BLSH Daily ETF","BLSG":"2倍做多BLSH ETF-Leverage Shares","BK4136":"纸材料包装","UFPT":"UFP技术","BK4112":"金融交易所和数据","BK4198":"医疗保健用品"},"translate_title":"UFP Technologies(UFPT)利润率跌至11.3%考验看涨的医疗技术增长叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSX":0.6,"BLSG":0.6,"UFPT":1.98},"content_text":"UFP Technologies (UFPT) has put fresh numbers on the board for Q1 2026, with recent quarterly revenue sitting around US$148.9 million in Q4 2025, basic EPS of US$2.28 and trailing twelve month EPS of US$8.87 helping frame the latest report. Over the last year, the company has seen total revenue move from US$504.4 million on a trailing basis in Q4 2024 to US$602.8 million in Q4 2025. Over the same period, trailing net income excluding extra items shifted from US$59.0 million to US$68.3 million and EPS went from US$7.69 to US$8.87, alongside earnings growth of 15.8% and a small margin step down from 11.7% to 11.3%. This keeps the focus firmly on profitability quality and where margins go next. See our full analysis for UFP Technologies. With the numbers on the table, the next step is to set these results against the main narratives around UFP Technologies to see which stories hold up and which start to look stretched. See what the community is saying about UFP Technologies NasdaqCM:UFPT Earnings & Revenue History as at May 2026 AdvertisementMargins Hold at Around 11% Despite Cost Pressures  Trailing net profit margin sits at 11.3%, a small step down from 11.7% a year earlier, while trailing net income excluding extra items moved from US$59.0 million to US$68.3 million over the same period. Bears highlight customer concentration and labor issues as threats to profitability, and the slight margin dip gives that view something to point to, yet:\n     Annual earnings still grew 15.8% on a trailing basis, which runs against the idea that cost and workforce issues are already heavily eroding profits. Multi year earnings growth of 29.8% per year suggests the business has previously absorbed pressures like rising input costs and acquisitions while keeping margins in a relatively tight range.    Bears argue these margins are more fragile than they look, so it is worth seeing how their full thesis stacks up against the longer term track record. 🐻 UFP Technologies Bear Case 15.8% Earnings Growth Meets Slower Pace Than 5 Year Trend  On a trailing basis, earnings grew 15.8% over the last year compared with a 29.8% per year average over five years, while trailing twelve month revenue moved from US$504.4 million in Q4 2024 to US$602.8 million in Q4 2025. Bullish investors argue UFP can sustain above market growth thanks to MedTech exposure, recurring programs, and efficiency gains, and the data both supports and stretches that view:\n     The 15.8% earnings growth and higher trailing EPS of US$8.87 versus US$7.69 a year earlier are consistent with a business that has continued to grow, rather than stalling. The gap between the latest 15.8% growth and the 29.8% five year average shows the recent pace is more moderate than the longer trend, which bulls need to reconcile with expectations for strong future expansion.    Bulls point to margins, growth history, and MedTech exposure as reasons this slower year might be a pause rather than a change in pattern. 🐂 UFP Technologies Bull Case Valuation Sits Between Peer Multiples And DCF Fair Value  At a share price of US$212.43, UFP Technologies trades on a trailing P/E of 24x, close to peers at 24.1x and a little above the US Medical Equipment industry at 23.6x, while a DCF fair value of US$354.88 sits well above both the market price and the consensus analyst target of US$324.50. Consensus narrative suggests the company’s investments and margin outlook can justify that gap, yet the numbers give a mixed message:\n     Peer like P/E and 15.8% trailing earnings growth do not obviously flag an outlier premium, which fits with a market that is pricing UFP similarly to comparable stocks despite its multi year growth record. The DCF fair value being materially above the current price, and above the consensus target, assumes the recent moderation from 29.8% five year earnings growth to 15.8% is not a lasting shift, which is something each investor needs to test against their own expectations.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for UFP Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. If the mix of bull and bear arguments here feels finely balanced, take a closer look at the underlying data and decide quickly where you stand. Then round out your view by checking the 2 key rewards. See What Else Is Out There UFP Technologies is facing a slower 15.8% earnings pace than its 29.8% multi year trend and modest margin compression, which leaves valuation expectations more finely balanced. If that mix of moderating growth and a full looking 24x P/E makes you cautious, compare it with companies screened for 51 high quality undervalued stocks to see where the market may be pricing in more upside today.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}